Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
NeoGenomics Follow-On Offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the…
REGENXBIO Inc. $175.5 Million Common Stock Offering
Davis Polk advised the representatives of the underwriters in connection with the $175.5 million offering of 2,700,000…
BeiGene Ltd. HK$7.08 Billion (US$903 Million) Public Offering on the Hong Kong Stock Exchange
Davis Polk advised the underwriters and the joint global coordinators in the public offering of BeiGene, Ltd. on the…
Davis Polk Advises Pernix on Private Exchange Offers
Davis Polk advised Pernix Therapeutics Holdings, Inc. in connection with separate private exchange offers for its existing…
Davis Polk Advises AC Immune SA on Its $117.5 Million Follow-On Public Offering and Subscription Rights Offerings
Davis Polk advised AC Immune SA in connection with its $117.5 million U.S. follow-on public offering. AC Immune sold 8,500…
Teladoc, Inc. $348.9 Million Common Stock Offering
Davis Polk advised the underwriter in connection with a $348.9 million SEC-registered offering of 5,263,740 shares of common…
Constellation Pharmaceuticals Initial Public Offering
Davis Polk advised the representatives of the several underwriters in connection with the $60 million initial public…
Allakos Inc. Initial Public Offering
Davis Polk advised the underwriters in connection with an initial public offering of 8,203,332 shares of common stock of…
Davis Polk Advises Auris Medical Holding AG on Its Offering of Common Shares and Warrants
Davis Polk advised Auris Medical Holding AG on a public offering of common shares and warrants. The common shares are listed…
CytomX Therapeutics, Inc. Follow-On Offering
Davis Polk advised the joint book-running managers in connection with the $125 million public offering of common stock of…